About aprea therapeutics inc - APRE
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Doylestown, PA.
APRE At a Glance
Aprea Therapeutics, Inc.
3805 Old Easton Road
Doylestown, Pennsylvania 18902
| Phone | 1-617-463-9385 | Revenue | 285.76K | |
| Industry | Pharmaceuticals: Major | Net Income | -12,599,569.00 | |
| Sector | Health Technology | Employees | 8 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
APRE Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 19.518 |
| Price to Book Ratio | 0.562 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.628 |
| Enterprise Value to Sales | -29.026 |
| Total Debt to Enterprise Value | N/A |
APRE Efficiency
| Revenue/Employee | 35,719.875 |
| Income Per Employee | -1,574,946.125 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.014 |
APRE Liquidity
| Current Ratio | 5.629 |
| Quick Ratio | 5.629 |
| Cash Ratio | 5.281 |
APRE Profitability
| Gross Margin | 92.401 |
| Operating Margin | -4,631.119 |
| Pretax Margin | -4,409.159 |
| Net Margin | -4,409.159 |
| Return on Assets | -63.135 |
| Return on Equity | -74.581 |
| Return on Total Capital | -95.676 |
| Return on Invested Capital | -74.581 |
APRE Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |